Array Biopharma Drug Patent Portfolio
Array Biopharma owns 2 orange book drugs protected by 21 US patents Given below is the list of Array Biopharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9562016 | Preparation of and formulation comprising a MEK inhibitor | 18 Oct, 2033 | Active |
| US9598376 | Preparation of and formulation comprising a MEK inhibitor | 18 Oct, 2033 | Active |
| US9980944 | Preparation of and formulation comprising a MEK inhibitor | 18 Oct, 2033 | Active |
| US9474754 | Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor | 05 Aug, 2033 | Active |
| US10258622 | Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate | 21 Nov, 2032 | Active |
| US9387208 | Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate | 21 Nov, 2032 | Active |
| US9763941 | Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate | 21 Nov, 2032 | Active |
| US9314464 | Compounds and compositions as protein kinase inhibitors | 04 Jul, 2031 | Active |
| US8501758 | Compounds and compositions as protein kinase inhibitors | 04 Mar, 2031 | Active |
| US10005761 | Compounds and compositions as protein kinase inhibitors | 27 Aug, 2030 | Active |
| US9593099 | Compounds and compositions as protein kinase inhibitors | 27 Aug, 2030 | Active |
| US9593100 | Compounds and compositions as protein kinase inhibitors | 27 Aug, 2030 | Active |
| US9850229 | Compounds and compositions as protein kinase inhibitors | 27 Aug, 2030 | Active |
| US9850230 | Compounds and compositions as protein kinase inhibitors | 27 Aug, 2030 | Active |
| USRE49556 | Compounds and compositions as protein kinase inhibitors | 27 Feb, 2030 | Active |
| US8541575 | 3,4-diarylpyrazoles as protein kinase inhibitors | 26 Feb, 2030 | Active |
| US8946250 | 3,4-diarylpyrazoles as protein kinase inhibitors | 23 Jul, 2029 | Active |
| US7777050 | N3 alkylated benzimidazole derivatives as MEK inhibitors | 13 Mar, 2026 | Expired |
| US8178693 | N3 alkylated benzimidazole derivatives as MEK inhibitors | 13 Mar, 2023 | Expired |
| US8193229 | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors | 13 Mar, 2023 | Expired |
| US8513293 | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal | 13 Mar, 2023 | Expired |
Latest Legal Activities on Array Biopharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Array Biopharma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination -Election Required | 20 May, 2025 | US8178693 |
| Maintenance Fee Reminder Mailed | 07 Apr, 2025 | US8513293 |
| Interim Patent Term Extension Granted | 24 Feb, 2025 | US8178693 |
| Interim Patent Term Extension Granted | 24 Feb, 2025 | US7777050 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Jan, 2025 | US9763941 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Jan, 2025 | US9850229 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Jan, 2025 | US8541575 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Jan, 2025 | US9850230 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Jan, 2025 | US9850229 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 03 Jan, 2025 | USRE49556 |
| FDA Final Eligibility Letter | 18 Dec, 2024 | US8178693 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Aug, 2024 | US9593100 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Aug, 2024 | US9593100 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Aug, 2024 | US9598376 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Aug, 2024 | US9593099 |
Array Biopharma Drug Patents' Oppositions Filed in EPO
Array Biopharma drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 19, 2018, by Generics [Uk] Limited (Trading As Mylan). This opposition was filed on patent number EP15177189A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15177189A | Apr, 2018 | Generics [UK] Limited (trading as Mylan) | Revoked |
Array Biopharma's Family Patents
Array Biopharma drugs have patent protection in a total of 58 countries. It's US patent count contributes only to 15.8% of its total global patent coverage. 8 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Array Biopharma Drug List
Given below is the complete list of Array Biopharma's drugs and the patents protecting them.
1. Braftovi
Braftovi is protected by 15 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9474754 | Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor |
05 Aug, 2033
(7 years from now)
| Active |
| US10258622 | Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate |
21 Nov, 2032
(6 years from now)
| Active |
| US9387208 | Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
21 Nov, 2032
(6 years from now)
| Active |
| US9763941 | Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
21 Nov, 2032
(6 years from now)
| Active |
| US9314464 | Compounds and compositions as protein kinase inhibitors |
04 Jul, 2031
(5 years from now)
| Active |
| US8501758 | Compounds and compositions as protein kinase inhibitors |
04 Mar, 2031
(4 years from now)
| Active |
| US10005761 | Compounds and compositions as protein kinase inhibitors |
27 Aug, 2030
(4 years from now)
| Active |
| US8501758 | Compounds and compositions as protein kinase inhibitors |
27 Aug, 2030
(4 years from now)
| Active |
| US9593099 | Compounds and compositions as protein kinase inhibitors |
27 Aug, 2030
(4 years from now)
| Active |
| US9593100 | Compounds and compositions as protein kinase inhibitors |
27 Aug, 2030
(4 years from now)
| Active |
| US9850229 | Compounds and compositions as protein kinase inhibitors |
27 Aug, 2030
(4 years from now)
| Active |
| US9850230 | Compounds and compositions as protein kinase inhibitors |
27 Aug, 2030
(4 years from now)
| Active |
| USRE49556 | Compounds and compositions as protein kinase inhibitors |
27 Feb, 2030
(3 years from now)
| Active |
| US8541575 | 3,4-diarylpyrazoles as protein kinase inhibitors |
26 Feb, 2030
(3 years from now)
| Active |
| US8946250 | 3,4-diarylpyrazoles as protein kinase inhibitors |
23 Jul, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Braftovi's drug page
2. Mektovi
Mektovi is protected by 11 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9562016 | Preparation of and formulation comprising a MEK inhibitor |
18 Oct, 2033
(7 years from now)
| Active |
| US9598376 | Preparation of and formulation comprising a MEK inhibitor |
18 Oct, 2033
(7 years from now)
| Active |
| US9980944 | Preparation of and formulation comprising a MEK inhibitor |
18 Oct, 2033
(7 years from now)
| Active |
| US9314464 | Compounds and compositions as protein kinase inhibitors |
04 Jul, 2031
(5 years from now)
| Active |
| US10005761 | Compounds and compositions as protein kinase inhibitors |
27 Aug, 2030
(4 years from now)
| Active |
| US9593100 | Compounds and compositions as protein kinase inhibitors |
27 Aug, 2030
(4 years from now)
| Active |
| US9850229 | Compounds and compositions as protein kinase inhibitors |
27 Aug, 2030
(4 years from now)
| Active |
| US7777050 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
13 Mar, 2026
(2 days ago)
| Expired |
| US8178693 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
13 Mar, 2023
(3 years ago)
| Expired |
| US8193229 | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors |
13 Mar, 2023
(3 years ago)
| Expired |
| US8513293 | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal |
13 Mar, 2023
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mektovi's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List